Related Experiment Video
Updated: Jul 13, 2026

Synthesis of Indoxyl-glycosides for Detection of Glycosidase Activities
Published on: May 27, 2015
Novel imidazo[1,2-a]pyridine-based α-glucosidase inhibitors: synthesis, biological evaluations, and computational
Maryam Norouzbahari1, Zahra Emamgholipour2, Fariba Peytam2,3
1Faculty of Pharmacy, Final International University, Kyrenia via Mersin 10, TRNC, Catalkoy, Turkey.
Abstract:
In an attempt to identify novel α‑glucosidase inhibitors, a new series of substituted imidazo[1,2‑a]pyridine derivatives (10a-10ab) was designed, synthesized, and evaluated for their inhibitory activities. All compounds exhibited potent inhibition, with IC50 values ranging from 12.01 to 93.01 µM, significantly better than acarbose IC50 = 750.02 µM). SAR analysis highlighted the critical role of para‑substitution on the benzamide ring, especially methoxy groups. The most potent compound, 10s (IC50 = 12.01 µM), acted as a competitive inhibitor (Ki = 21 µM) with no α‑amylase inhibition, indicating high selectivity. It was non‑cytotoxic up to 100 µM. Circular dichroism, fluorescence spectroscopy, and thermodynamic analysis revealed strong ligand-enzyme interactions mainly driven by hydrophobic forces. Molecular docking and 200 ns MD simulations, including MM‑GBSA calculations, supported stable binding of 10s within the active site. Collectively, these results introduce imidazo[1,2-a]pyridine derivative 10s as a promising lead compound for the development of novel α-glucosidase inhibitors in further studies.
Related Concept Videos
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are typically...
Dipeptidyl Peptidase 4 Inhibitors
Oral Hypoglycemic Agents: Biguanides and Glitazones
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Oral Hypoglycemic Agents: Glinides
Oral Hypoglycemic Agents: Sulfonylureas

